- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05341193
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
PD-1 Inhibitor and Bevacizumab Replace Cisplatin in Induction, Concurrent, and/or Adjuvant Therapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Xi Ding, MD
- Telefonnummer: 86-19880836260
- E-Mail: dingxi@sysucc.org.cn
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
-
Kontakt:
- Ming-Yuan Chen, MD,PhD
- Telefonnummer: 86-20-8734-2422
- E-Mail: chenmy@sysucc.org.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Voluntary participation with Written informed consent.
- Age ≥ 18 years and ≤ 65 years.
- Histologically confirmed with Nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type).
- Original clinical staged as III-IVa (according to the 8th AJCC edition).
- Stage III patients should meet the criteria of EBV DNA≥4000 cps/ml.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
Patients must have adequate organ function:
- White blood cell count (WBC)≥4.0×109 /L, Hemoglobin ≥ 90g/L, Platelet count ≥100×109/L.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN),serum total bilirubin (TBIL) ≤2.0 times the upper limit of normal (ULN) .
- Adequate renal function: creatinine clearance rate≥60 ml/min or Creatinine ≤1.5× upper limit of normal value.
- INR, APTT≤1.5 x ULN.
Exclusion Criteria:
- Subjects with recurrent or metastatic nasopharyngeal carcinoma.
- Histologically or cytologically confirmed with keratinizing squamous cell carcinoma of the nasopharynx.
- Prior therapy with systemic therapy for nasopharyngeal carcinoma.
- Prior exposure to immune checkpoint inhibitors,including anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies.
- Prior exposure to antiangiogenic agents.
- Tumor invasion to the intracranial with clinical symptoms accompanied by cerebral edema, requiring hormone therapy.
- Any grade ≥2 bleeding event (according to CTCAE 5.0) occurred within 4 weeks prior to enrollment.
- Subjects with an active, known or suspected autoimmune disease.
- Subjects with clinically significant cardiovascular and cerebrovascular diseases.
- Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs.
- Subjects with previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency.
- Subjects with arterial / venous thrombosis events occurred within 6 months of the first dose.
- Women in the period of pregnancy, lactation, or reproductive without effective contraceptive measures.
- Seropositivity for human immunodeficiency virus (HIV).
- Known history of other malignancies (except cured basal cell carcinoma or carcinoma in situ of the cervix).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: low risk
Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab every 3 weeks for a maximum of 1 year after radiotherapy.
|
Induction therapy: Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy. Concurrent therapy: Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy. Adjuvant therapy: Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy. Radiation: Intensity-modulated radiotherapy. |
Experimental: high risk
Patients will receive induction therapy with toripalimab plus bevacizumab and gemcitabine every 3 weeks for 3 cycles before radiotherapy, then followed by IMRT and concurrent therapy with toripalimab plus bevacizumab for 2 cycles, then followed by adjuvant therapy with toripalimab and bevacizumab every 3 weeks for a maximum of 1 year after radiotherapy.
|
Induction therapy: Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy. Concurrent therapy: Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy. Adjuvant therapy: Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy. Radiation: Intensity-modulated radiotherapy. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
grade ≥3 nasopharyngeal necrosis or hemorrhage
Zeitfenster: At the end of each cycle (each cycle is 21 days)
|
Incidence of nasopharyngeal necrosis or massive hemorrhage (grade ≥3). Grade ≥3 hemorrhage: Grade 3, Transfusion indicated; invasive intervention indicated; hospitalization. Grade 4, Life-threatening consequences; urgent intervention indicated (e.g., tracheotomy or intubation). Grade 5, death. Grade ≥3 nasopharyngeal necrosis: Grade 3, Severe pain; unable to adequately aliment or hydrate orally; limiting self care ADL. Grade 4, Life-threatening consequences; urgent intervention indicated. Grade 5, death. |
At the end of each cycle (each cycle is 21 days)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Objective response rate
Zeitfenster: 3 weeks after indution therapy; 3 months after concurrent therapy
|
The proportion of patients whose tumors shrink to a certain size and maintain such size for a certain period of time, including patients with complete response (CR) and partial response (PR).
|
3 weeks after indution therapy; 3 months after concurrent therapy
|
Progression-free survival
Zeitfenster: 3 year
|
Progress-free survival is calculated from the date of enrollment to the date of the first progression at any site or death from any cause or censored at the date of the last follow-up.
|
3 year
|
Overall survival
Zeitfenster: 3 year
|
Overall survival is calculated from the date of enrollment to the date of the death from any cause or censored at the date of the last follow-up.
|
3 year
|
Locoregional failure-free survival (LRRFS)
Zeitfenster: 3 year
|
Defined as the time from registration to local or regional relapse, or death from any cause.
|
3 year
|
Distant metastasis-free survival (DMFS)
Zeitfenster: 3 year
|
Defined as the time from registration to distant metastasis, or death from any cause.
|
3 year
|
Incidence rate of adverse events (AEs)
Zeitfenster: 3 year
|
Analysis of acute and late adverse events (AEs) are evaluated.
Numbers of patients of treatment-related adverse events (acute toxicity) and late radiation toxicities were assessed by CTCAE v5.0.
|
3 year
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Neubildungen, Drüsen und Epithelien
- Rachenneoplasmen
- Otorhinolaryngologische Neubildungen
- Kopf-Hals-Neubildungen
- Nasopharyngeale Erkrankungen
- Rachenkrankheiten
- Stomatognathe Erkrankungen
- Otorhinolaryngologische Erkrankungen
- Nasopharyngeale Neoplasmen
- Karzinom
- Nasopharynxkarzinom
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Antineoplastische Mittel, immunologische
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Gemcitabin
- Bevacizumab
Andere Studien-ID-Nummern
- SYSUCC-CMY-2022-0416
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nasopharynxkarzinom
-
Gustave Roussy, Cancer Campus, Grand ParisUnbekanntLOKAL FORTGESCHRITTENES UNDIFFERENZIERTES KARZINOM NASOPHARYNGEAL TYP UCNTFrankreich
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnbekanntInvasiver Brustkrebs | Duktales Carcinoma in situ der BrustKanada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Abgeschlossen
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)BeendetBrustkrebsVereinigte Staaten
-
University of AarhusUnbekanntCarcinoma in situ des GebärmutterhalsesDänemark
-
University of Southern CaliforniaBeendetBrustkrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...Aktiv, nicht rekrutierendDuktales Carcinoma in situ der BrustVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Brookdale University Hospital Medical CenterUnbekanntCarcinoma in situ des Gebärmutterhalses | Zervikale intraepitheliale Neoplasien | Hochgradige zervikale intraepitheliale NeoplasieVereinigte Staaten
-
Thomas Jefferson UniversityRekrutierungBrustkrebs | Invasiver Brustkrebs | Carcinoma in situ der BrustVereinigte Staaten
Klinische Studien zur Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... und andere MitarbeiterNoch keine RekrutierungRezidivierendes NasopharynxkarzinomChina
-
Zhujiang HospitalRekrutierung
-
Fudan UniversityNoch keine RekrutierungIntrahepatisches Cholangiokarzinom
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... und andere MitarbeiterNoch keine RekrutierungRezidivierendes NasopharynxkarzinomChina
-
Shouyao Holdings (Beijing) Co. LTDRekrutierungFortgeschrittener BauchspeicheldrüsenkrebsChina
-
Abbisko Therapeutics Co, LtdRekrutierungFortgeschrittener BauchspeicheldrüsenkrebsChina
-
Air Force Military Medical University, ChinaRekrutierung
-
Shanghai Junshi Bioscience Co., Ltd.Aktiv, nicht rekrutierendFortgeschrittenes hepatozelluläres Karzinom (HCC)China
-
Peking UniversityAbgeschlossenFortgeschrittener GallengangskrebsChina
-
Sun Yat-sen UniversityNoch keine RekrutierungNasopharynxkarzinomChina